Telehealth Treatment of Veterans with Alcohol Misuse at Risk for Cardiovascular Disease

对有心血管疾病风险的酗酒退伍军人进行远程医疗治疗

基本信息

  • 批准号:
    10182749
  • 负责人:
  • 金额:
    --
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2021
  • 资助国家:
    美国
  • 起止时间:
    2021-05-01 至 2026-04-30
  • 项目状态:
    未结题

项目摘要

Background: Cardiovascular disease (CVD) is the most common cause of death in Veterans. CVD-related deaths are over twice as likely in patients with comorbid alcohol misuse, due in part to alcohol misuse directly exacerbating several modifiable factors that lead to CVD. No interventions exist targeting both these comorbidities, and current VA/DoD treatment guidelines for comorbid alcohol misuse in primary care are ineffective. Because alcohol misuse is often a recurrent problem, and the dominant driver of treatment recommendations, timely treatment of these Veterans’ CVD risk in conjunction with alcohol misuse treatment in may be critical for developing clinical traction with CVD risk. Dr. Blalock seeks to refine a telehealth intervention and acquire necessary training throughout this CDA-2 proposal to begin his career as an independent VA health services researcher who seeks to improve the effectiveness and reach of behavioral health treatments for Veterans with comorbid behavioral health problems. Significance/Impact: 9-32% of the entire Veteran population has comorbid alcohol misuse and modifiable elevated CVD risk. This high-risk population is entirely preventable, but is undertreated and understudied. The proposed CDA research would be the first to directly target this high-risk population. This research is highly relevant to Veteran health, VHA priorities, and HSR&D priorities because the combined intervention targets and telehealth approaches address critical gaps in treatment timeliness and access. Specific Aims: Aim 1 –Characterize a national cohort of Veterans with alcohol misuse and modifiable CVD risk, their alcohol services utilization, and clinical outcomes. Aim 2 – Qualitatively assess barriers to treatment for Veterans with alcohol misuse and CVD risk across multiple stakeholders. Aim 3 – Use a successive cohort design to iteratively develop an intervention based on patient feedback. Aim 4 – Test the acceptability and feasibility of an intervention to reduce alcohol misuse and CVD risk in Veterans. Innovation: This application is highly innovative in its attempt to address for the first time: 1) perceptions of barriers to treatment in this population, 2) the utility of a combined intervention for alcohol misuse and CVD risk, 3) multimorbid patient preferences for timing of treatments for multiple different targets, and 4) the sustainability of health behavior habits in VA formed by an intervention using “implementation intentions.” Methodology: Aim 1 will use electronic health records to examine the status of key health criteria and services utilization among Veterans with alcohol misuse, both with and without comorbid CVD risk. Aim 2 will use qualitative interviews of both Veterans with comorbid alcohol misuse and elevated modifiable CVD risk, their providers across different settings, and systems-level stakeholders to assess current treatment barriers. Aim 3 will employ a successive cohort design to iteratively test the proposed intervention with rapid and early feedback from multiple Veteran cohorts. Aim 4 will test a refined intervention based on feedback from Aims 2 and 3 to determine the acceptability to Veteran patients, as well as the feasibility of recruitment, randomization, and intervention. Next Steps/Implementation: Beginning in Aim 1, a systems-level advisory board will be convened semi- annually with the goal of eliciting feedback throughout intervention development to aid implementation. By the end of the 3rd year of the CDA-2, an IIR application will be submitted to fund a randomized comparative effectiveness trial of the Aim 3 intervention. Results will also be presented to local Veterans engagement panels associated with “VetREP.” Additional feedback from OCC and OMHSP operations partners, and implementation considerations gleaned from utilization patterns and care settings in Aim 4, will allow rapid development of a post-IIR implementation plan. Additional training in cost effectiveness and implementation science will also give Dr. Blalock the skills to follow through with additional research and implementation.
背景:心血管疾病(CVD)是退伍军人最常见的死亡原因。CVD-related

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Daniel V Blalock其他文献

Daniel V Blalock的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Daniel V Blalock', 18)}}的其他基金

Telehealth Treatment of Veterans with Alcohol Misuse at Risk for Cardiovascular Disease
对有心血管疾病风险的酗酒退伍军人进行远程医疗治疗
  • 批准号:
    10388227
  • 财政年份:
    2021
  • 资助金额:
    --
  • 项目类别:

相似海外基金

Collaborative Research: Overlooked Oxidation of Aqueous Alcohols: Kinetics, Mechanism, and Relevance to Water Reuse
合作研究:被忽视的水醇氧化:动力学、机制以及与水回用的相关性
  • 批准号:
    2304861
  • 财政年份:
    2023
  • 资助金额:
    --
  • 项目类别:
    Continuing Grant
STTR Phase I: Development of Modular Reactors to Convert Methane to Alcohols at Low Temperatures
STTR 第一阶段:开发在低温下将甲烷转化为醇的模块化反应器
  • 批准号:
    2151256
  • 财政年份:
    2023
  • 资助金额:
    --
  • 项目类别:
    Standard Grant
Development of amine-dehydrogenase and lyase biocatalysts for the sustainable manufacturing of unnatural chiral amino acids and amino alcohols
开发胺脱氢酶和裂解酶生物催化剂,用于可持续生产非天然手性氨基酸和氨基醇
  • 批准号:
    2870226
  • 财政年份:
    2023
  • 资助金额:
    --
  • 项目类别:
    Studentship
Collaborative Research: Overlooked Oxidation of Aqueous Alcohols: Kinetics, Mechanism, and Relevance to Water Reuse
合作研究:被忽视的水醇氧化:动力学、机制以及与水回用的相关性
  • 批准号:
    2304860
  • 财政年份:
    2023
  • 资助金额:
    --
  • 项目类别:
    Continuing Grant
Postdoctoral Fellowship: MPS-Ascend: Development of Selective Reaction Schemes for Photoactivation of Alcohols
博士后奖学金:MPS-Ascend:醇光活化选择性反应方案的开发
  • 批准号:
    2316541
  • 财政年份:
    2023
  • 资助金额:
    --
  • 项目类别:
    Fellowship Award
Development of phosphorylation of alcohols in protein based on the structural modification of phosphoenolpyruvate
基于磷酸烯醇丙酮酸结构修饰的蛋白质醇磷酸化研究进展
  • 批准号:
    22KJ1152
  • 财政年份:
    2023
  • 资助金额:
    --
  • 项目类别:
    Grant-in-Aid for JSPS Fellows
Nickel Cross-Coupling Cascades with α-Heteroatom Radicals to Prepare Sterically Hindered Alcohols and Amines
镍与α-杂原子自由基交叉偶联级联制备位阻醇和胺
  • 批准号:
    10604535
  • 财政年份:
    2023
  • 资助金额:
    --
  • 项目类别:
Towards a better understanding of the effect of the pentafluorosulfanyl group on the lipophilicity and acid/base properties of alcohols and amines
更好地了解五氟硫基对醇和胺的亲脂性和酸/碱性质的影响
  • 批准号:
    571856-2021
  • 财政年份:
    2022
  • 资助金额:
    --
  • 项目类别:
    Alliance Grants
Pd-Catalyzed C(sp3)-H Functionalizations Directed by Free Alcohols and Boc-Protected Amines
由游离醇和 Boc 保护的胺引导的 Pd 催化 C(sp3)-H 官能化
  • 批准号:
    10606508
  • 财政年份:
    2022
  • 资助金额:
    --
  • 项目类别:
MPS-Ascend: Nickel/Photoredox-Catalyzed C(sp3)–C(sp3) Cross-Coupling Between Alkyl Halides and Activated Alcohols
MPS-Ascend:镍/光氧化还原催化的 C(sp3)→C(sp3) 烷基卤化物和活化醇之间的交叉偶联
  • 批准号:
    2213210
  • 财政年份:
    2022
  • 资助金额:
    --
  • 项目类别:
    Fellowship Award
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了